• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.

作者信息

Banach Maciej, Jankowski Piotr, Jóźwiak Jacek, Cybulska Barbara, Windak Adam, Guzik Tomasz, Mamcarz Artur, Broncel Marlena, Tomasik Tomasz, Rysz Jacek, Jankowska-Zduńczyk Agnieszka, Hoffman Piotr, Mastalerz-Migas Agnieszka

机构信息

Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Lodz, Poland.

1 Department of Cardiology, Interventional Electrocardiology and Hypertension, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland.

出版信息

Arch Med Sci. 2017 Feb 1;13(1):1-45. doi: 10.5114/aoms.2017.64712. Epub 2016 Dec 19.

DOI:10.5114/aoms.2017.64712
PMID:28144253
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5206369/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee0/5206369/73aa784fd50b/AMS-13-28931-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee0/5206369/26e19a1266e2/AMS-13-28931-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee0/5206369/73aa784fd50b/AMS-13-28931-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee0/5206369/26e19a1266e2/AMS-13-28931-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee0/5206369/73aa784fd50b/AMS-13-28931-g002.jpg

相似文献

1
PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.2016年家庭医生血脂异常管理的PoLA/CFPiP/PCS指南
Arch Med Sci. 2017 Feb 1;13(1):1-45. doi: 10.5114/aoms.2017.64712. Epub 2016 Dec 19.
2
PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021.2021年波兰脂质紊乱诊断与治疗的PoLA/CFPiP/PCS/PSLD/PSD/PSH指南
Arch Med Sci. 2021 Nov 8;17(6):1447-1547. doi: 10.5114/aoms/141941. eCollection 2021.
3
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).ESC/EAS 血脂异常管理指南：欧洲心脏病学会（ESC）和欧洲动脉粥样硬化学会（EAS）血脂异常管理工作组
Eur Heart J. 2011 Jul;32(14):1769-818. doi: 10.1093/eurheartj/ehr158. Epub 2011 Jun 28.
4
[Management of dyslipidaemias -  present and future. Guidelines of the Angiology Section of the Slovak Medical Chamber (2013)].[血脂异常的管理——现状与未来。斯洛伐克医学协会血管病学分会指南（2013年）]
Vnitr Lek. 2013 Oct;59(10):932-8.
5
Can genetic testing help in the management of dyslipidaemias?基因检测能否有助于血脂异常的管理？
Curr Opin Lipidol. 2020 Aug;31(4):187-193. doi: 10.1097/MOL.0000000000000690.
6
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).2016年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南：欧洲心脏病学会（ESC）和欧洲动脉粥样硬化学会（EAS）血脂异常管理工作组编写，欧洲心血管预防与康复协会（EACPR）提供特别贡献。
Atherosclerosis. 2016 Oct;253:281-344. doi: 10.1016/j.atherosclerosis.2016.08.018. Epub 2016 Sep 1.
7
[Update Dyslipidaemias - Comments on the 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias].[血脂异常更新——对2016年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南的评论]
Dtsch Med Wochenschr. 2017 Jun;142(11):816-820. doi: 10.1055/s-0042-123146. Epub 2017 May 31.
8
Lateral gene transfer of family A DNA polymerases between thermophilic viruses, aquificae, and apicomplexa.嗜热病毒、泉古菌和顶复门生物之间 A 家族 DNA 聚合酶的侧向基因转移。
Mol Biol Evol. 2013 Jul;30(7):1653-64. doi: 10.1093/molbev/mst078. Epub 2013 Apr 22.
9
Physician behaviors to promote informed decisions for prostate cancer screening: a National Research Network study.促进前列腺癌筛查知情决策的医生行为：一项国家研究网络研究
J Cancer Educ. 2014 Jun;29(2):345-9. doi: 10.1007/s13187-014-0613-2.
10
Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels.波兰心脏病学会（PCS）和波兰脂质协会（PoLA）专家关于脂蛋白(a)水平升高的诊断和管理的建议。
Arch Med Sci. 2024 Jan 31;20(1):8-27. doi: 10.5114/aoms/183522. eCollection 2024.

引用本文的文献

1
2024 Polish recommendations for the management of familial hypercholesterolemia in children and adolescents.2024年波兰儿童和青少年家族性高胆固醇血症管理建议
Arch Med Sci. 2024 Nov 22;20(6):1741-1753. doi: 10.5114/aoms/196329. eCollection 2024.
2
2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders.波兰实验室诊断学会和波兰脂质协会2024年脂质代谢紊乱实验室诊断指南。
Arch Med Sci. 2024 Mar 18;20(2):357-374. doi: 10.5114/aoms/186191. eCollection 2024.
3
Atorvastatin on Treatment of Nonalcoholic Fatty Liver Disease Patients.

本文引用的文献

1
Practice setting and secondary prevention of coronary artery disease.冠心病的实践环境与二级预防
Arch Med Sci. 2018 Aug;14(5):979-987. doi: 10.5114/aoms.2017.65236. Epub 2017 Jan 19.
2
Intensive LDL-cholesterol lowering therapy and neurocognitive function.强化 LDL-胆固醇降低治疗与神经认知功能。
Pharmacol Ther. 2017 Feb;170:181-191. doi: 10.1016/j.pharmthera.2016.11.001. Epub 2016 Nov 16.
3
Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement.他汀类药物治疗依从性不佳与心血管残留风险：仍需大幅改善。
阿托伐他汀治疗非酒精性脂肪性肝病患者
Chonnam Med J. 2024 Jan;60(1):13-20. doi: 10.4068/cmj.2024.60.1.13. Epub 2024 Jan 25.
4
Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia.脂蛋白(a)与杂合子家族性高胆固醇血症患者的 DNA 损伤有关。
Sci Rep. 2024 Jan 31;14(1):2564. doi: 10.1038/s41598-024-52571-w.
5
Body Composition and Cardiovascular Risk: A Study of Polish Military Flying Personnel.身体成分与心血管风险：波兰军事飞行人员的一项研究。
Metabolites. 2023 Oct 21;13(10):1102. doi: 10.3390/metabo13101102.
6
Effect of the Nutritional Intervention Program on Body Weight and Selected Cardiometabolic Factors in Children and Adolescents with Excess Body Weight and Dyslipidemia: Study Protocol and Baseline Data.营养干预计划对超重和血脂异常儿童和青少年体重及部分心血管代谢因素的影响：研究方案和基线数据。
Nutrients. 2023 Aug 19;15(16):3646. doi: 10.3390/nu15163646.
7
Metabolic syndrome - a new definition and management guidelines: A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, "Club 30" Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons.代谢综合征——新定义与管理指南：波兰高血压学会、波兰肥胖治疗学会、波兰脂质协会、波兰肝脏研究协会、波兰家庭医学学会、波兰生活方式医学学会、波兰心脏病学会预防与流行病学分会、波兰心脏病学会“30俱乐部”以及波兰外科医生学会代谢与减重手术分会联合立场文件
Arch Med Sci. 2022 Aug 30;18(5):1133-1156. doi: 10.5114/aoms/152921. eCollection 2022.
8
Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP).逐步诊断和管理他汀类药物相关肌肉症状患者的安慰剂/反安慰剂效应：国际脂质专家组（ILEP）的立场文件。
J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1596-1622. doi: 10.1002/jcsm.12960. Epub 2022 Mar 10.
9
Cardiovascular risk and metabolic profile of Polish citizens from Lower Silesia. First signs of metabolic crisis?下西里西亚波兰公民的心血管风险和代谢状况。代谢危机的最初迹象？
Arch Med Sci. 2020 Oct 14;18(3):617-623. doi: 10.5114/aoms.2020.99922. eCollection 2022.
10
Comparison of low-density lipoprotein cholesterol level calculated using the modified Martin/Hopkins estimation or the Friedewald formula with direct homogeneous assay measured low-density lipoprotein cholesterol.使用改良的Martin/Hopkins估算方法或Friedewald公式计算的低密度脂蛋白胆固醇水平与直接匀相测定法测得的低密度脂蛋白胆固醇水平的比较。
Arch Med Sci. 2020 Aug 3;18(3):577-586. doi: 10.5114/aoms.2020.97847. eCollection 2022.
Int J Cardiol. 2016 Dec 15;225:184-196. doi: 10.1016/j.ijcard.2016.09.075. Epub 2016 Sep 26.
4
PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk.过氧化物酶体增殖物激活受体激动剂、动脉粥样硬化性血脂异常与心血管风险。
Curr Pharm Des. 2017 Mar 26;23(6):894-902. doi: 10.2174/1381612822666161006151134.
5
Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms?他汀类药物相关肌病及生物标志物的探索：我们能否有效预测他汀类药物相关肌肉症状？
Drug Discov Today. 2017 Jan;22(1):85-96. doi: 10.1016/j.drudis.2016.09.001. Epub 2016 Sep 12.
6
Subfractions of high-density lipoprotein (HDL) and dysfunctional HDL in chronic kidney disease patients.慢性肾病患者高密度脂蛋白（HDL）亚组分及功能失调的HDL
Arch Med Sci. 2016 Aug 1;12(4):844-9. doi: 10.5114/aoms.2016.60971. Epub 2016 Jul 1.
7
Prevalence of familial hypercholesterolemia: a meta-analysis of six large, observational, population-based studies in Poland.家族性高胆固醇血症的患病率：波兰六项大型基于人群的观察性研究的荟萃分析。
Arch Med Sci. 2016 Aug 1;12(4):687-96. doi: 10.5114/aoms.2016.59700. Epub 2016 May 5.
8
Changes in the prevalence, treatment, and control of hypercholesterolemia and other dyslipidemias over 10 years in Poland: the WOBASZ study.波兰高胆固醇血症及其他血脂异常的患病率、治疗和控制情况在10年间的变化：WOBASZ研究
Pol Arch Med Wewn. 2016 Jul 19;126(9):642-652. doi: 10.20452/pamw.3464.
9
What is the association of lipid levels and incident stroke?血脂水平与新发中风之间有什么关联？
Int J Cardiol. 2016 Oct 1;220:890-4. doi: 10.1016/j.ijcard.2016.06.091. Epub 2016 Jun 23.
10
Factors related to the effectiveness of hypercholesterolemia treatment following hospitalization for coronary artery disease.冠心病住院后高胆固醇血症治疗效果的相关因素。
Pol Arch Med Wewn. 2016 Jun 23;126(6):388-94. doi: 10.20452/pamw.3447.